Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroDefense has chosen to advance a compound licensed to it by Schering-Plough into investigational new drug-enabling preclinical studies for the prevention and treatment of poliovirus infections.
Subscribe to our email newsletter
Schering-Plough has licensed to ViroDefense the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales.
ViroDefense claims that the lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND-enabling studies will commence with V-073.
Marc Collett, president of ViroDefense, said: “We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio. This is clearly a humanitarian gesture on their part.”